Kari Hooper, MD
Anatomic Pathology & Clinical Pathology · Oklahoma City, OKNPI 1760681381
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations.
Across 47 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$220
- Blueprint Medicines Corporation$109
- Regeneron Healthcare Solutions, Inc.$67
- Daiichi Sankyo Inc.$55
- Ipsen Biopharmaceuticals, Inc$55
- Novartis$55
- plus $445 from 19 others
What the payments were for
- Food & beverage$1,006100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $220 |
| Blueprint Medicines Corporation | 2 | $109 |
| Regeneron Healthcare Solutions, Inc. | 3 | $67 |
| Daiichi Sankyo Inc. | 3 | $55 |
| Ipsen Biopharmaceuticals, Inc | 3 | $55 |
| Novartis | 3 | $55 |
| Amgen | 3 | $54 |
| ADC Therapeutics America, Inc. | 2 | $41 |
| Eisai Inc. | 2 | $39 |
| Incyte Corporation | 2 | $34 |
| Exelixis Inc. | 2 | $31 |
| Boehringer Ingelheim | 1 | $25 |
| Seagen Inc. | 1 | $24 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $18 |
| Roche Diagnostics Corporation | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Adaptive Biotechnologies Corporation | 1 | $14 |
| GSK | 1 | $14 |
| Bayer | 1 | $14 |
How this compares
$1,006 in reported general payments places this provider in the 85th percentile of 72 anatomic pathology & clinical pathology providers in Oklahoma.
See all anatomic pathology & clinical pathology providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other anatomic pathology & clinical pathology in Oklahoma City
- Lewis HassellOklahoma City$1K
- Zoltan LaszikOklahoma City$824
- Derek IrwinOklahoma City$404
- Ruchi SachdevOklahoma City$383
- James SchnabelOklahoma City$330
- Dena ShibibOklahoma City$256
- James BrinkworthOklahoma City$160
- Chad HamiltonOklahoma City$158
- Paula RogersOklahoma City$140
- Brian BeschOklahoma City$133
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.